Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2026-05-15 16:05:45 ET · period of report 2026-05-13 · accession 0001193125-26-226652 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 16:05 | 2026-05-13 | KPTI | Cheng Sohanya Roshan | EVP, Chief Commercial Off | A - Grant | $0.00 | +947 | 108.3K | +0.9% | $0 | |
| 2026-05-15 16:05 | 2026-05-14 | KPTI | Cheng Sohanya Roshan | EVP, Chief Commercial Off | S - Sale | $9.50 | -324 | 107.9K | -0.3% | -$3,078 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-13 | A | A | 947 | $0.00 | 108,264 | D | — | — | (F1) Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. |
| 2 | Common | Common Stock | 2026-05-14 | S | D | 324 | $9.50 | 107,940 | D | — | — | (F2) This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person. |